RxDoctor Payments Data

Scott Becker, MD

Gastroenterology · Austin, TXNPI 1912982596

Payments from drug & device makers

$160,174in general payments, 2019–2025

Across 814 payments — averaging $196.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$126K
  • Phathom Pharmaceuticals, Inc.$11K
  • Pfizer$11K
  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Bristol Myers Squibb$1K
  • plus $5K from 34 others

What the payments were for

  • Speaking & faculty fees$13,73544%
  • Travel & lodging$3,00310%
  • Food & beverage$14,18746%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,174 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$108,302
Medicare patients
528
Services billed
817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$323,631
XifaxanRifaximin55$229,399
CreonLipase/Protease/Amylase13$35,371
LinzessLinaclotide37$32,876
Mesalamine27$22,016
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates148$9,444
Dexlansoprazole DrDexlansoprazole26$6,542
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C31$4,199
Budesonide DrBudesonide44$3,850
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag30$3,657
ClenpiqSod Picosulf/Mag Ox/Citric Ac21$3,536
Omeprazole249$3,482
Balsalazide Disodium29$2,771
Pantoprazole Sodium181$2,136
Famotidine197$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,363$233,59886 claims
AbbVieCreon, Linzess$4,544$68,24750 claims
Braintree Laboratories, Inc.Suflave$40$3,65730 claims
Ferring Pharmaceuticals Inc.Clenpiq$35$3,53621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →